Experimental Models of Anxiety for Drug Discovery and Brain Research

2016 ◽  
pp. 271-291 ◽  
Author(s):  
Peter C. Hart ◽  
Carisa L. Bergner ◽  
Amanda N. Smolinsky ◽  
Brett D. Dufour ◽  
Rupert J. Egan ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Brain Research ◽  
Experimental Models

Experimental Models of Anxiety for Drug Discovery and Brain Research

2009 ◽  
pp. 299-321 ◽  
Author(s):  
Peter C. Hart ◽  
Carisa L. Bergner ◽  
Amanda N. Smolinsky ◽  
Brett D. Dufour ◽  
Rupert J. Egan ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Brain Research ◽  
Experimental Models

Experimental models for anxiolytic drug discovery in the era ofomesandomics

2011 ◽  
Vol 6 (7) ◽  
pp. 755-769 ◽  
Author(s):  
Adam Stewart ◽  
Siddharth Gaikwad ◽  
Peter Hart ◽  
Evan Kyzar ◽  
Andrew Roth ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Experimental Models ◽  
Anxiolytic Drug

scholarly journals Improving Cancer Drug Discovery by Studying Cancer across the Tree of Life

2019 ◽  
Vol 37 (1) ◽  
pp. 11-17 ◽  
Author(s):  
Jason A Somarelli ◽  
Amy M Boddy ◽  
Heather L Gardner ◽  
Suzanne Bartholf DeWitt ◽  
Joanne Tuohy ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Tumor Development ◽  
Experimental Models ◽  
Cancer Drug ◽  
Success Rates ◽  
Comparative Oncology ◽  
Protective Mechanisms ◽  
Cancer Drug Discovery ◽  
Models Of Disease ◽  
The Cost

Abstract Despite a considerable expenditure of time and resources and significant advances in experimental models of disease, cancer research continues to suffer from extremely low success rates in translating preclinical discoveries into clinical practice. The continued failure of cancer drug development, particularly late in the course of human testing, not only impacts patient outcomes, but also drives up the cost for those therapies that do succeed. It is clear that a paradigm shift is necessary if improvements in this process are to occur. One promising direction for increasing translational success is comparative oncology—the study of cancer across species, often involving veterinary patients that develop naturally-occurring cancers. Comparative oncology leverages the power of cross-species analyses to understand the fundamental drivers of cancer protective mechanisms, as well as factors contributing to cancer initiation and progression. Clinical trials in veterinary patients with cancer provide an opportunity to evaluate novel therapeutics in a setting that recapitulates many of the key features of human cancers, including genomic aberrations that underly tumor development, response and resistance to treatment, and the presence of comorbidities that can affect outcomes. With a concerted effort from basic scientists, human physicians and veterinarians, comparative oncology has the potential to enhance the cost-effectiveness and efficiency of pipelines for cancer drug discovery and other cancer treatments.

scholarly journals Zebrafish as an Emerging Model for Bioassay-Guided Natural Product Drug Discovery for Neurological Disorders

Medicines ◽  
2019 ◽  
Vol 6 (2) ◽  
pp. 61 ◽  
Author(s):  
Arjun Pitchai ◽  
Rajesh Kannan Rajaretinam ◽  
Jennifer L. Freeman
Keyword(s):  
Natural Products ◽  
Drug Discovery ◽  
Natural Product ◽  
Neurological Disorders ◽  
Experimental Models ◽  
Bioactive Natural Products ◽  
Natural Product Research ◽  
Model Platform

Most neurodegenerative diseases are currently incurable, with large social and economic impacts. Recently, there has been renewed interest in investigating natural products in the modern drug discovery paradigm as novel, bioactive small molecules. Moreover, the discovery of potential therapies for neurological disorders is challenging and involves developing optimized animal models for drug screening. In contemporary biomedicine, the growing need to develop experimental models to obtain a detailed understanding of malady conditions and to portray pioneering treatments has resulted in the application of zebrafish to close the gap between in vitro and in vivo assays. Zebrafish in pharmacogenetics and neuropharmacology are rapidly becoming a widely used organism. Brain function, dysfunction, genetic, and pharmacological modulation considerations are enhanced by both larval and adult zebrafish. Bioassay-guided identification of natural products using zebrafish presents as an attractive strategy for generating new lead compounds. Here, we see evidence that the zebrafish’s central nervous system is suitable for modeling human neurological disease and we review and evaluate natural product research using zebrafish as a vertebrate model platform to systematically identify bioactive natural products. Finally, we review recently developed zebrafish models of neurological disorders that have the potential to be applied in this field of research.

scholarly journals Experimental Models for Aging and their Potential for Novel Drug Discovery

2018 ◽  
Vol 16 (10) ◽  
pp. 1466-1483 ◽  
Author(s):  
Jaume Folch ◽  
Oriol Busquets ◽  
Miren Ettcheto ◽  
Elena Sánchez-López ◽  
Mercè Pallàs ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Experimental Models ◽  
Novel Drug

scholarly journals Preclinical experimental models of drug metabolism and disposition in drug discovery and development

2012 ◽  
Vol 2 (6) ◽  
pp. 549-561 ◽  
Author(s):  
Donglu Zhang ◽  
Gang Luo ◽  
Xinxin Ding ◽  
Chuang Lu
Keyword(s):  
Drug Discovery ◽  
Drug Metabolism ◽  
Experimental Models ◽  
Drug Discovery And Development
Sign in / Sign up

Export Citation Format

Share Document